Insider Purchases: Inside the Buy
Tag: insider buying
Fox Factory: Left for Roadkill or Setting Up a Suspension Rebound?
Fox Factory (FOXF) went from high-flyer to face-plant, trading over 90% below its peak — yet the CEO and big institutions keep buying. Is this a stealth value opportunity or a suspension story that never quite rebounds? Let’s dig in, with jokes and numbers.
Biohaven Just Went Through Hell — But Its CEO and Directors Still See an Angel
Biohaven’s stock plunged after a brutal FDA rejection — but insiders didn’t blink. They bought millions of dollars’ worth of shares, doubled down on their pipeline, and kickstarted a leaner, more focused strategy. Bold turnaround play or biotech heartburn waiting to happen? Here's the FUNanc1al deep dive.
CEO/COB at Cigna Is Buying CI. Is He Signaling: Time To Buy?
Cigna’s CEO is buying big — and Wall Street is paying attention. With earnings up, a pharmacy-benefit shake-up underway, and valuations looking healthy, CI might just be the quiet value stock investors have been waiting for. Let’s break it down — and have fun doing it. 😎💊📈
CEO Bought Shares of Booz Allen Hamilton: Time to Indulge
Booz Allen just flashed insider conviction: CEO Horacio Rozanski purchased ~$2M of BAH stock. Despite near-term revenue pressure from funding delays, the firm sports a record backlog, mission-critical AI/cyber programs, and steady capital returns. We unpack the bull/bear, valuation, and what could flip the narrative from pause to play.
A Director Bought Shares of Coca-Cola (KO) Hoping They’ll Sparkle; Should You—Or Will They Fizzle Out?
A fresh insider buy from new director Max Levchin adds fizz to Coca-Cola’s already solid fundamentals: mid-single-digit organic growth, fortress cash flow, and a Dividend King pedigree. We break down the bull/bear case, valuation, and why KO still shines—especially on dips.
CEO, COB, President All Bought Shares of FTI Consulting (FCN). It’s the Same Person—Still… Should You Buy Too?
FTI Consulting just posted record EPS while its tri-titled chief bought $1.13M of stock and the board added $500M to buybacks. A cycle-balanced franchise that compounds through booms, busts, and boardroom “oh-no’s.”
Executive Chairman Adds To His Already Huge Stake in Ryan Specialty Holdings. Should You Follow His Lead?
Executive Chairman Patrick Ryan just added $14M to his already massive stake in Ryan Specialty Holdings. With strong revenue growth and heavy institutional backing, is this insurance play worth your portfolio — or is it still too pricey?
CEO and Michael Burry of Scion Asset Management Have Bought Shares of Bruker Corporation (BRKR). Should You Too, Or Is It a Value Trap?
CEO insider buys + Michael Burry’s 15% portfolio bet make Bruker (BRKR) hard to ignore. But is it a hidden gem in science… or a costly lab experiment?
Insiders Pile Into Opendoor (OPEN) as New CEO Kasra Nejatian Bets on an ‘AI-First, Software-First’ Future — Should You Join the Cult Stock Rally?
Insiders are buying, retail traders are chanting, and Opendoor has a new AI-first CEO. From near-delisting to cult stock darling — is OPEN worth the hype?
Novocure (NVCR): From Electric Fields to Fighting Cancer — and Maybe Lifting Portfolios?
Novocure is zapping cancer cells with Tumor Treating Fields — and maybe giving investors a shock of opportunity. With insiders and institutions piling in, can NVCR rebound 94% from its crash? ⚡📈